• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.

作者信息

Li Xuanzong, Wang Ruozheng, Wang Linlin

机构信息

Department of Radiation Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China; Department of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China.

Department of Radiation Oncology, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, China.

出版信息

Lung Cancer. 2020 Dec;150:256-258. doi: 10.1016/j.lungcan.2020.09.021. Epub 2020 Sep 30.

DOI:10.1016/j.lungcan.2020.09.021
PMID:33012556
Abstract
摘要

相似文献

1
MET-mutant cancer and immune checkpoint inhibitors: A large database analysis.MET突变癌症与免疫检查点抑制剂：一项大型数据库分析
Lung Cancer. 2020 Dec;150:256-258. doi: 10.1016/j.lungcan.2020.09.021. Epub 2020 Sep 30.
2
A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis".对《MET突变癌症与免疫检查点抑制剂：一项大型数据库分析》的回复
Lung Cancer. 2020 Dec;150:259-260. doi: 10.1016/j.lungcan.2020.11.001. Epub 2020 Nov 5.
3
Increased Hepatotoxicity Associated with Sequential Immune Checkpoint Inhibitor and Crizotinib Therapy in Patients with Non-Small Cell Lung Cancer.免疫检查点抑制剂序贯克唑替尼治疗与非小细胞肺癌患者肝毒性增加相关。
J Thorac Oncol. 2019 Jan;14(1):135-140. doi: 10.1016/j.jtho.2018.09.001. Epub 2018 Sep 8.
4
NF1-Mutant Cancer and Immune Checkpoint Inhibitors: A Large Database Analysis.NF1 突变型癌症与免疫检查点抑制剂：一项大型数据库分析
Clin Lung Cancer. 2021 Sep;22(5):480-481. doi: 10.1016/j.cllc.2021.03.002. Epub 2021 Mar 16.
5
Crizotinib in MET Exon 14-Mutated or MET-Amplified in Advanced Disease Non-Small Cell Lung Cancer: A Retrospective, Single Institution Experience.克唑替尼治疗 MET 外显子 14 突变或 MET 扩增的晚期非小细胞肺癌：一项回顾性、单机构经验。
Oncology. 2022;100(9):467-474. doi: 10.1159/000525188. Epub 2022 Jun 9.
6
Effect of targeted therapy and immunotherapy on advanced nonsmall-cell lung cancer outcomes in the real world.靶向治疗和免疫治疗对真实世界中晚期非小细胞肺癌结局的影响。
Cancer Med. 2022 Jan;11(1):86-93. doi: 10.1002/cam4.4427. Epub 2021 Nov 16.
7
Mutation of MET Y1230 as an Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping.MET Y1230突变作为MET外显子14跳跃的非小细胞肺癌中克唑替尼耐药的一种获得性机制
J Thorac Oncol. 2017 Jul;12(7):e89-e90. doi: 10.1016/j.jtho.2017.02.017.
8
Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation.一例具有MET外显子14跳跃突变的肺腺癌患者对新辅助克唑替尼的病理完全缓解
Clin Lung Cancer. 2019 Mar;20(2):e137-e141. doi: 10.1016/j.cllc.2018.11.003. Epub 2018 Nov 20.
9
Identification of a Novel MET Exon 14 Skipping Variant Coexistent with EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment with Afatinib and Crizotinib.在对阿法替尼和克唑替尼联合治疗敏感的肺腺癌中鉴定出一种与EGFR突变共存的新型MET外显子14跳跃变体
J Thorac Oncol. 2019 Apr;14(4):e70-e72. doi: 10.1016/j.jtho.2018.11.026.
10
Identification of a Novel MET Exon 14 Skipping Variant in Lung Adenocarcinoma Sensitive to Crizotinib Treatment.在对克唑替尼治疗敏感的肺腺癌中鉴定出一种新型MET外显子14跳跃变异体
J Thorac Oncol. 2021 Mar;16(3):e17-e19. doi: 10.1016/j.jtho.2020.11.014.

引用本文的文献

1
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target.非小细胞肺癌（NSCLC）中的MET：走过“漫长而曲折的道路”寻找靶点。
Cancers (Basel). 2023 Sep 28;15(19):4779. doi: 10.3390/cancers15194779.
2
Interferon Regulatory Factor 4 Correlated With Immune Cells Infiltration Could Predict Prognosis for Patients With Lung Adenocarcinoma.与免疫细胞浸润相关的干扰素调节因子4可预测肺腺癌患者的预后。
Front Oncol. 2021 Jun 14;11:698465. doi: 10.3389/fonc.2021.698465. eCollection 2021.